VASODILATORS ARE widely used in the management of chronic congestive heart failure,' primarily because of their immediate hemodynamic efficacy.2 6 These hemodynamic studies have been carried out almost exclusively in patients at supine rest, though most patients with chronic congestive heart failure are symptomatic during exertion. The acute effects of vasodilators on exercise capacity in patients with congestive heart failure have not been clearly defined.
Exercise limitation in patients with heart failure is generally thought to be caused by an inability to increase cardiac output appropriately during exercise, thereby limiting oxygen transport to skeletal muscle,7' 8 and by excessive rise in pulmonary capillary pressure contributing to the premature onset of dyspnea.9 Cardiac output and pulmonary capillary pressure (or left ventricular filling pressure) are promptly and markedly improved by vasodilator drugs administered at rest. Whether these same parameters are altered by vasodilators during exercise is not known. Although vasodilators increase cardiac output and reduce left ventricular filling pressure at rest, they may not necessarily increase maximal exercise capacity. The effects of exercise itself on left ventricular outflow resistance are largely unknown. The fall in systemic vascular resistance that occurs during exercise would be expected to decrease the peripheral arteriolar component of left ventricular outflow resistance. 10 It is possible that this exercise-induced arteriolar dilation is not further augmented by vasodilator drugs, and that hemodynamics at maximal exercise are not altered. Indeed, in our preliminary experience, acute administration of nitrates did not alter maximal exercise capacity in heart failure."
Preliminary studies in patients with congestive heart failure have shown improved exercise performance during long-term treatment with nitrates, prazosin, and trimazosin.i 12, 13 The long-term response to these agents may not result from their immediate effects on left ventricular outflow resistance, but could be related to the chronic effects of sustained vasodilation on the cardiovascular system. There are no data currently available concerning acute impedance reduction and exercise capacity in patients with cardiomyopathy. The present study was designed to assess the effects of a single dose of vasodilators on exercise capacity and hemodynamics in patients with congestive heart failure due to myocardial disease. We tested an oral vasodilator regimen, hydralazine and isosorbide dinitrate, which has been used in the management of chronic congestive heart failure and produces acute hemodynamic changes similar to those of intravenous sodium nitroprusside.'4
Methods
We selected 22 patients with class II-III congestive heart failure (New York Heart Association criteria) from an outpatient clinic population. The cause of congestive heart failure was ischemic heart disease or primary myocardial disease. Ischemic heart disease was diagnosed by a history of documented acute myocardial infarction or by coronary arteriography, and primary myocardial disease was diagnosed when there was no evidence of any other cause for congestive heart failure. Patients with valvular insufficiency were included if previous cardiac catheterization data showed that the major cause of congestive heart failure was left ventricular dysfunction (ejection fraction below 40%) and not primary valvular disease. Patients with normally functioning prosthetic valves and persistent congestive heart failure were also included. Patients were selected because they were limited by shortness of breath or fatigue on exertion. Patients with angina were excluded as well as those with primary lung or valvular disease, acute myocardial infarction within the past 6 months, or intermittent claudication.
On the day of study, after obtaining written informed consent, patients were brought to an exercise laboratory located in an air conditioned room with uniform temperature and humidity. Patients were studied in the postabsorptive state, i.e., at least 2 hours after the ingestion of any food. All previous vasodilator and diuretic drugs were discontinued at least 24 hours before the study, while maintenance digitalis and antiarrhythmic drugs were continued. Because the hemodynamic action of the vasodilators lasts less than 12 hours, a 24-hour washout was considered adequate.4' The heart rate and ECG were monitored from a standard V5 lead. Blood pressure was measured by the cuff technique. Expired air was collected and passed in series through a Parkinson Cowan dry gas meter, a Beckman LB-2 carbon dioxide analyzer, and a Beckman OM-14 oxygen analyzer; the outputs were displayed on a Beckman RR-2 recorder, permitting continuous on-line monitoring of oxygen consumption and CO2 production. Cardiac output was measured by the carbon dioxide rebreathing method. This method has been validated during exercise in normal subjects, and we have validated its use in patients with congestive heart failure both at rest and during exercise. 5, 16 Details of this noninvasive, indirect Fick procedure have been described elsewhere. '7 Measurements were made at supine and sitting rest. Exercise was then begun on a Monark bicycle ergometer, beginning at 150 kilopond-meters/min (kpm/min) and increasing the work load by 150 kpm/min every 4 minutes until symptomatic maximum. Achievement of maximal aerobic exercise was verified by a significant increase in the respiratory exchange ratio.'8 19 All patients were limited by dyspnea or fatigue and no one stopped because of angina, arrhythmia, or electrocardiographic changes. After control exercise and recovery of supine heart rate and blood pressure to baseline levels, patients were given either hydralazine, 100 mg by mouth, and isosorbide dinitrate, 40 mg by mouth (group 1) or placebo tablets (group 2) in a random, double-blind fashion. Exercise was repeated 90 minutes after administration of the drugs. The drug doses and time intervals were based on our previous experience with this drug combination. '4 Mean arterial pressure was calculated as diastolic arterial pressure plus one-third of the pulse pressure. Systemic vascular resistance was calculated as the mean arterial pressure divided by cardiac output. Statistical analysis was performed using the paired t test to compare values before and after test drug within the same group, and the unpaired t test to compare values between treatment groups.
Results
Baseline characteristics of the two groups are shown in table 1 . There were no statistically significant differences between groups in age, body weight, clinical classification, or supine resting hemodynamics. All cases of valvular heart disease were due to mitral or aortic regurgitation from rheumatic heart disease. Patients 9 and 15 had mitral valve prostheses, and patient 18 had left ventricular dysfunction with mild aortic insufficiency (graded 2+ at catheterization) not requiring surgery. All patients had been on maintenance therapy with digitalis and diuretics. Ten patients had also been receiving vasodilator therapy for congestive heart failure; four of these were randomized to group 1. Eight of the 22 patients in the study had a resting cardiac index > 2.5 1/min/M2, despite being symptomatically in New York Heart Association class II or III heart failure.
Values at sitting rest and submaximal exercise levels are shown in figure 1 . At sitting rest, hydralazine-nitrate combination had no effect on oxygen consumption and produced a slight but statistically insignificant increase in heart rate and cardiac index; mean arterial pressure and systemic vascular resistance were significantly reduced after hydralazine-nitrate combination. The The lack of significant effects at peak exercise after hydralazine-nitrate combination might be because several patients did not have marked hemodynamic impairment at rest and therefore might not have been good responders to the vasodilator combination. Because of this, the seven patients who had an increase in cardiac index at sitting rest after hydralazinenitrate combination were analyzed separately. In this significance at the 300 kpm/min work load (3.51 ± 0.33 vs 4.02 ± 0.27 I/min/M2, p < 0.05). Systemic vascular resistance was also significantly reduced at the same work load on hydralazine-nitrate combination (15.1 ± 1.7 vs 11.8 ± 0.6 units, p < 0.05).
In contrast to the results observed during submaximal exercise, hydralazine-nitrate combination had no significant effects on exercise capacity or hemodynamics at maximal exercise (table 2). Since only a few patients were able to reach high work loads, i.e., > 300 kpm/min, statistical comparison at that level is not possible. The values in table 2 were therefore derived by comparing responses for each patient at his individual peak exercise load on each test. Only one patient in group 1 and three in group 2 exercised to different work loads (all higher) on the second exercise test. The pretreatment control exercise hemodynamics and exercise capacity, expressed as duration or maximal oxygen consumption, were not different between groups. Exercise capacity in terms of exercise duration or oxygen consumption at maximal exercise was not significantly increased by either hydralazine- 
Discussion
Patients with congestive heart failure experience the onset or worsening of symptoms during physical activity, and one of the major goals of treatment is to alleviate exertion-related symptomatology. One cause of symptoms during exertion is an inappropriate increase in left ventricular filling pressure, which leads to elevated pulmonary capillary pressure and premature onset of dyspnea; another is an inability to increase cardiac output appropriately, which leads to premature onset of fatigue. Cardiac output normally increases linearly with rising total body oxygen needs during exertion. The increase in cardiac output is accomplished by increases in heart rate, contractility and preload, and a presumed reduction in outflow resistance from a fall in peripheral resistance.7 8, 18 Patients with congestive heart failure may have impaired heart rate responses during exercise, as well as depressed myocardial contractility due to intrinsic heart disease.7 20 Preload in these patients is often elevated in the resting state; further increases of preload during exercise may not produce significant augmentation of cardiac output in congestive heart failure patients, who are usually operating on the plateau portion of their Frank-Starling curves. Indeed, a marked elevation of preload may simply lead to increased pulmonary vascular congestion. Little is known about the effects of exercise on outflow resistance, but we presume that it decreases as a result of the fall in peripheral resistance from arteriolar dilation in exercising skeletal muscle.
Since vasodilators increase cardiac output and decrease left ventricular filling pressure at rest, these agents could increase exercise capacity if the same hemodynamic effects were sustained during exercise. It has recently been reported that acute nitrate administration can improve exercise hemodynamics and capacity in patients with primary valvular heart disdilators. 21 The hemodynamic effects of vasodilators during exercise in patients with heart failure due to cardiomyopathy have not been reported. Experience in small numbers of patients has demonstrated increased treadmill exercise time in patients who have had long-term treatment with nitrates, prazosin and trimazosin. 8 12,13 An improvement in exercise tolerance could be due to the immediate, direct effects of the vasodilators in reducing left ventricular outflow resistance. It could also be due to the long-term effects of sustained reduction in outflow resistance on left ventricular function. Finally, exercise itself is a stimulus to arteriolar dilation and results in significant reduction in systemic vascular resistance; administration of vasodilator drugs may not augment this vasodilation and therefore may not further reduce left ventricular outflow resistance. These exercise-induced effects on arteriolar tone are most evident at high work loads and less evident at submaximal levels, where it is more likely that vasodilators could exert an additive effect.7
Indeed, in the present study we observed that the hydralazine-nitrate combination improved hemodynamics at submaximal exercise levels; however, at maximal exercise the vasodilator combination had no apparent effect on hemodynamics or on exercise capacity in terms of exercise duration or oxygen consumption. These results, therefore, should not necessarily be interpreted as negative because patients with congestive heart failure rarely exercise to maximal capacity. The fact that cardiac output was somewhat higher and systemic vascular resistance somewhat lower at submaximal exercise levels might make it more comfortable for patients to exercise at these levels with fewer symptoms. Although we did not measure left ventricular filling pressure in the present study, we have noted that acute administration of nitrates reduces the left ventricular filling pressure during exercise at submaximal levels." Borer et al. also reported reduced pulmonary arterial pressure during submaximal exercise after nitroglycerin administration in patients with valvular heart disease.2'
The failure of the vasodilators to increase maximal exercise capacity or alter hemodynamics at maximal exercise in the present study could be due to several mechanisms. First, it is possible that the vasodilator agents are incapable of significantly augmenting the arteriolar dilation induced by exercise itself at peak work loads. This might be related to the observation that patients with congestive heart failure have impaired responses to vasodilator stimuli, perhaps because of sodium in the vessel wall or edema of interstitial spaces.7 22 In addition, the increase in pulmonary capillary pressure during maximal exercise may not have been attenuated by the drug combination, as in our previous observations on the hemodynamic response to nitrates at maximal exercise." It is unlikely that hydralazine would have much additional effect on maximal exercise because it has minimal effects on ventricular filling pressure at rest.5' 1 ' Also, it is doubtful that the exercise test used was too strenuous. The work load increments were 1089 ease who might be particularly sensitive to vaso-VOL 59, No 6, JUNE 1979 linear and of the order of 1 met ( fig. 1) , which is an acceptable stress in patients with heart failure. 23 Another possibility is that the patients in this study were poor responders to vasodilators. This is suggested by the fact that cardiac output at rest failed to increase significantly after the hydralazine-nitrate combination in contrast to our previous experience with these drugs.'4 This attenuated response is probably related to the fact that eight of the 22 patients had a resting cardiac index > 2.5 1/min/M2. We have reported that the rise in cardiac output in response to nitroprusside and nitrates is less when the control cardiac output is normal.24 Yet this factor alone cannot explain our results because the patients with low cardiac output who responded well to the vasodilator combination also failed to show any change in maximal exercise capacity or exercise hemodynamics after hydralazine-nitrate combination.
Although a number of the patients in the present study had nearly normal resting cardiac outputs, this was still a very incapacitated group of patients. Total body oxygen consumption and cardiac output achieved during exercise were similar to values reported by other workers exercising patients with clinical class II or III congestive heart failure. Indeed, it was shown in these earlier studies that patients with significant and symptomatic congestive heart failure could not reach maximal oxygen consumption above 16 ml/kg/min.23 Only five of our 22 patients were able to increase oxygen consumption to this level and the average maximum for all patients was only 12 ml/kg/min.
The results of the present study should be interpreted cautiously. We designed this study primarily to assess the immediate effects of the first dose of vasodilators on exercise hemodynamics and exercise capacity. Also, we have assumed that cessation of previous vasodilator therapy for at least 24 hours is sufficient to eliminate carry-over effects. Under these conditions there were no significant differences observed after vasodilator administration. We therefore conclude that vasodilators do not immediately improve exercise capacity or maximal exercise hemodynamics in patients with congestive heart failure. Similar preliminary results have been reported after administration of hydralazine alone. 25 Further studies are needed to assess the effects of long-term vasodilator administration on exercise in patients with heart failure. Preliminary studies have already shown increased exercise duration with such therapy. In the meantime, the present study suggests that vasodilators can produce desirable hemodynamic responses at submaximal exercise and that vasodilator therapy might be immediately beneficial in allowing patients to exercise more comfortably at limited work loads. This is consistent with numerous clinical observations of symptomatic improvement in patients at rest or during their usual activities after administration of vasodilators 2, 6, 24, 26 
